HERG Screening Global Market Report 2024

The HERG screening market size has grown rapidly in recent years. It will grow from $1.42 billion in 2023 to $1.62 billion in 2024 at a compound annual growth rate (CAGR) of 14.2%. The expansion observed in the historical period can be attributed to several contributing factors, including the uptick in drug development activities, heightened regulatory requirements, increased awareness of cardiac safety considerations, and a rising incidence of cardiac disorders.

The HERG screening market size is expected to see rapid growth in the next few years. It will grow to $2.6 billion in 2028 at a compound annual growth rate (CAGR) of 12.5%. The projected growth in the forecast period can be attributed to the expansion of personalized medicine, a surge in outsourcing of drug development activities, the emergence of new markets and research avenues, and a heightened focus on non-cardiac safety assessments. Key trends anticipated in this period include advancements in in vitro models, the integration of genomic and proteomic data, progress in computational approaches, a specific emphasis on pediatric drug safety, and increased collaborations for data sharing and standardization.

The anticipated increase in the number of patients with heart disorders is set to drive the growth of the HERG screening market. Heart disorders, encompassing various conditions affecting the heart and blood vessels, pose serious health risks and are influenced by factors such as unhealthy lifestyles, an aging population, genetic predispositions, diabetes, and metabolic syndrome. HERG screening plays a crucial role in identifying potential drug candidates, preventing adverse cardiac events, particularly torsade de pointes (TdP), and ultimately improving patient outcomes. As of May 2023, the Centers for Disease Control and Prevention reported that in the US, 1 in 20 adults aged 20 and older had cardiovascular diseases, with 695,000 people suffering from cardiovascular diseases in 2021, resulting in 375,476 deaths. Additionally, in March 2022, the Office for National Statistics reported 19,440 heart attack-related deaths in the UK in 2020, rising to 20,061 in 2021. The increasing prevalence of heart disorders is a pivotal factor driving the growth of the HERG screening market.

Key companies in the HERG screening market are actively focusing on innovative solutions, including GLP-certified HERG screening services, to enhance cardiac safety assessments during drug development processes. GLP-certified HERG screening involves screening the human ether-à-go-go related gene (hERG) using the conventional whole-cell patch-clamp technique, ensuring compliance with regulatory guidelines such as ICH S7A and ICH S7B. These guidelines are critical for safety pharmacology studies in drug development. For example, in August 2023, Metrion Biosciences Ltd., a UK-based pharmaceutical company, introduced the GLP-certified hERG screening service. This service is designed to support small-molecule therapeutic development, complement the existing cardiac safety service portfolio, and employ the conventional whole-cell patch-clamp technique to assess potential cardiac liabilities before entering Phase 1 clinical trials. It provides regulatory guidance for safety pharmacology studies and offers high-quality biology services for ion channel targets.

In September 2021, ApconiX, a UK-based company specializing in fast and efficient HERG screening for drug discovery projects, partnered with PhysioStim to establish a European Center of Excellence for preclinical cardiovascular safety evaluation. The collaboration aims to provide a comprehensive range of preclinical cardiac safety tests, including automated electrophysiology for HERG screening, CiPA ion channel assays, and GLP compliance assays. PhysioStim, a France-based preclinical contract research organization, specializes in cardiac safety and cardiovascular studies.

Major companies operating in the HERG screening market are Eurofins-Cerep SA., Aviva Biosciences Inc., AstraZeneca Public Limited Company, Merck KGaA, Charles River Laboratories Inc., Abcam Public Limited Company, Molecular Devices LLC, Caliper Life Sciences Inc., Crprotex Limited, ChanTest Corporation, Creative bioarray Inc., Cellular Dynamics International Inc., Nanion Technologies, Essen Bioscience, ABR-Affinity BioReagents Inc., ACEA Biosciences Inc., Metrion biosciences Inc., Aurora Biomed Inc., Aureus Sciences, RedShift BioAnalytics, B'SYS GmbH, Cambridge Bioscience Ltd., Sophion Bioscience Inc., Fluxion Biosciences Inc., ChemAxon Ltd.

North America was the largest region in the HERG screening market in 2023. Asia-Pacific is expected to be the fastest growing region in the forecast period. The regions covered in the herg screening market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the herg screening market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Human Ether-à-go-go-related gene (HERG) screening is a crucial step in evaluating the potential cardiotoxic effects of a drug or compound. This screening process plays a vital role in preclinical safety assessment within the drug discovery and development phases, serving to guarantee the safety and effectiveness of newly developed therapeutic agents.

HERG screening encompasses two primary categories, gene KCNH2 and mutant KCNH2. The KCNH2 gene, also recognized as the human ether-à-go-go-related gene (hERG) or hERG gene, encodes the alpha subunit of a potassium ion channel pivotal in the regulation of the heart's electrical activity. This gene encompasses diverse ion channels, including both voltage-gated and ligand-gated variations. Its applications span across various therapeutic domains, including antiarrhythmics, antipsychotics, antibiotics, and others, underscoring its critical role in multiple medical contexts.

The HERG screening market research report is one of a series of new reports that provides HERG screening market statistics, including HERG screening industry global market size, regional shares, competitors with a HERG screening market share, detailed HERG screening market segments, market trends and opportunities, and any further data you may need to thrive in the HERG screening industry. This HERG screening market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The HERG screening market includes revenues earned by entities by providing services such as in vitro HERG assays, patch clamp electrophysiology, data analysis and interpretation, consultation and regulatory support, and customized assay development. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.